Circulation:在缺失CETP的情况下,ADCY9失活可抵抗动脉粥样硬化

2018-10-24 MedSci MedSci原创

药物基因组学研究表明ADCY9基因型决定了CETP(胆甾醇酯转移蛋白)抑制剂达塞曲匹对心血管事件和动脉粥样硬化成像的影响。ADCY9和CETP活性相互作用的潜在机制尚未明确。研究人员采用进行或不进行CETP基因改造(CETPtgAdcy9Gt/Gt和CETPtgAdcy9WT)的Adcy9失活型(Adcy9Gt/Gt)和野生型(WT)小鼠进行动脉粥样硬化试验,予以注射表达功能获得性突变PCSK9(

药物基因组学研究表明ADCY9基因型决定了CETP(胆甾醇酯转移蛋白)抑制剂达塞曲匹对血管事件和动脉粥样硬化成像的影响。ADCY9和CETP活性相互作用的潜在机制尚未明确。

研究人员采用进行或不进行CETP基因改造(CETPtgAdcy9Gt/Gt和CETPtgAdcy9WT)的Adcy9失活型(Adcy9Gt/Gt)和野生型(WT)小鼠进行动脉粥样硬化试验,予以注射表达功能获得性突变PCSK9(9型枯草杆菌蛋白酶/Kexin样前蛋白转化酶)的AAV8(腺相关病毒血清型8),并予以0.75%胆固醇饮食喂养16周。

与WT小鼠相比,Adcy9Gt/Gt小鼠动脉粥样硬化减少65%(p<0.01),斑块中CD68阳性巨噬细胞聚集和增殖也均减少(p<0.05),而且股动脉内皮依赖性血管舒张提高(p<0.01)。选择性药物阻断显示,NO、环氧化酶和内皮依赖性超极化通路均可促进Adcy9Gt/Gt小鼠血管舒张(p<0.01)。Adcy9Gt/Gt小鼠的动脉内皮细胞,相比WT小鼠的,可显著降低脾细胞的粘附性(p<0.05)。Adcy9Gt/Gt小鼠体重增加比胆固醇饮食的WT增加的多;这一点与全身脂肪组织量增加有关(p<0.01)。与WT小鼠相比,Adcy9Gt/Gt小鼠的喂养效率提高(P<0.01),同时心脏RR间隔延长(P<0.05),夜间心率变异性增加(p=0.0572)。在CETPtgAdcy9Gt/Gt小鼠中,Adcy9失活所诱导的对动脉粥样硬化、内皮功能、体重增加、脂肪组织体积和饲料效率的影响均消失(p>0.05)。

Adcy9失活可抵抗动脉粥样硬化,但只发生在CETP活性缺失的情况下。该抗动脉粥样硬化效应可能是由于动脉壁中巨噬细胞聚集、增殖减少以及内皮功能和自主张力增强所导致的。


原始出处:


本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1944564, encodeId=2cdd19445643f, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sun Dec 23 18:47:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558251, encodeId=519c1558251fb, content=<a href='/topic/show?id=be69451200' target=_blank style='color:#2F92EE;'>#CETP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4512, encryptionId=be69451200, topicName=CETP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2db14951266, createdName=tidiq, createdTime=Fri Oct 26 12:47:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564260, encodeId=07081564260cb, content=<a href='/topic/show?id=be69451200' target=_blank style='color:#2F92EE;'>#CETP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4512, encryptionId=be69451200, topicName=CETP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2db14951266, createdName=tidiq, createdTime=Fri Oct 26 12:47:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350407, encodeId=62b335040ed7, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba101609906, createdName=happsf, createdTime=Wed Oct 24 21:50:58 CST 2018, time=2018-10-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1944564, encodeId=2cdd19445643f, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sun Dec 23 18:47:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558251, encodeId=519c1558251fb, content=<a href='/topic/show?id=be69451200' target=_blank style='color:#2F92EE;'>#CETP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4512, encryptionId=be69451200, topicName=CETP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2db14951266, createdName=tidiq, createdTime=Fri Oct 26 12:47:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564260, encodeId=07081564260cb, content=<a href='/topic/show?id=be69451200' target=_blank style='color:#2F92EE;'>#CETP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4512, encryptionId=be69451200, topicName=CETP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2db14951266, createdName=tidiq, createdTime=Fri Oct 26 12:47:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350407, encodeId=62b335040ed7, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba101609906, createdName=happsf, createdTime=Wed Oct 24 21:50:58 CST 2018, time=2018-10-24, status=1, ipAttribution=)]
    2018-10-26 tidiq
  3. [GetPortalCommentsPageByObjectIdResponse(id=1944564, encodeId=2cdd19445643f, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sun Dec 23 18:47:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558251, encodeId=519c1558251fb, content=<a href='/topic/show?id=be69451200' target=_blank style='color:#2F92EE;'>#CETP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4512, encryptionId=be69451200, topicName=CETP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2db14951266, createdName=tidiq, createdTime=Fri Oct 26 12:47:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564260, encodeId=07081564260cb, content=<a href='/topic/show?id=be69451200' target=_blank style='color:#2F92EE;'>#CETP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4512, encryptionId=be69451200, topicName=CETP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2db14951266, createdName=tidiq, createdTime=Fri Oct 26 12:47:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350407, encodeId=62b335040ed7, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba101609906, createdName=happsf, createdTime=Wed Oct 24 21:50:58 CST 2018, time=2018-10-24, status=1, ipAttribution=)]
    2018-10-26 tidiq
  4. [GetPortalCommentsPageByObjectIdResponse(id=1944564, encodeId=2cdd19445643f, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sun Dec 23 18:47:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558251, encodeId=519c1558251fb, content=<a href='/topic/show?id=be69451200' target=_blank style='color:#2F92EE;'>#CETP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4512, encryptionId=be69451200, topicName=CETP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2db14951266, createdName=tidiq, createdTime=Fri Oct 26 12:47:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564260, encodeId=07081564260cb, content=<a href='/topic/show?id=be69451200' target=_blank style='color:#2F92EE;'>#CETP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4512, encryptionId=be69451200, topicName=CETP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f2db14951266, createdName=tidiq, createdTime=Fri Oct 26 12:47:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350407, encodeId=62b335040ed7, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba101609906, createdName=happsf, createdTime=Wed Oct 24 21:50:58 CST 2018, time=2018-10-24, status=1, ipAttribution=)]
    2018-10-24 happsf

    学习

    0

相关资讯

Circulation:蛋白酶激活受体-2参与血管炎症和动脉粥样硬化的发生

凝血系统与血管炎症密切相关,但其机制尚不明确。近期有研究表明蛋白酶激活受体(PAR)-2是激活因子X的主要受体,在血管细胞和白细胞中均有表达,提示PAR-2可能参与炎症病理过程。现研究人员对PAR-2在血管炎症和动脉粥样硬化形成中的作用进行研究。研究人员建立了一种缺乏系统PAR-2表达的脂蛋白E缺陷的小鼠(PAR-2-/-ApoE-/-)。还通过骨髓移植建立ApoE-/- 小鼠,缺乏或仅在骨髓(B

Nat Commun:橄榄油预防心脏病?关键在血浆蛋白

有关橄榄油、鱼油、坚果等高不饱和脂肪食物可预防心血管疾病的报道已屡见不鲜,但其中原理却不明朗。9月6日,发表在《Nature Communications》杂志上的一项最新研究从血浆蛋白层面上为我们为带来了解释。

EBioMedicine:抗-丙二醛IgM抗体或可降低心脏病风险

在线发表于《EBioMedicine》杂志上的一项研究表明,抗-丙二醛IgM抗体的循环水平较低时与发生冠心病(CHD)相关。

Diabetic Med:糖尿病老年人中抑郁症状的患病率和相关性:社区动脉粥样硬化风险(ARIC)研究

近日,国际杂志 《Diabetic Med》上在线发表一项关于糖尿病老年人中抑郁症状的患病率和相关性:社区动脉粥样硬化风险(ARIC)研究。研究目的是记录老年人血糖谱中当前抑郁症状和抑郁史的患病率,并检查健康状况和医疗保健满意度,获取和利用的衡量标准是否可解释糖尿病状态下当前抑郁症状患病率的差异。 研究人员对参加2011 - 2013年动脉粥样硬化社区风险(ARIC)研究的6226名67-9

JACC:血脂促进动脉粥样硬化观点-强调LDL-C累积暴露,终生最适LDL-C或为70~80 mg/dl

近期,JACC杂志阐述了血脂对心血管健康的影响,并提出总动脉粥样硬化负荷这一新指标用于评估终生心血管事件风险,并表示应该重新定义一级预防以及重置最佳血脂目标值。提出总动脉粥样硬化负荷新指标:LDL-C水平×累积暴露时间文章指出,LDL-C与心血管疾病风险的因果关系取决于LDL-C水平和累积暴露时间。年龄乘以LDL-C水平可以计算出总动脉粥样硬化负荷(如图1),这是影响终生心血管事件的关键指标。

Circulation:ERV1/ChemR23信号可通过调节巨噬细胞氧化低密度脂蛋白的摄取和吞噬作用来预防动脉粥样硬化

血管炎症消退能力受损,除了会增强促炎信号,还在动脉粥样硬化中发挥重要作用。通过12/15脂氧合酶通路形成的促溶性脂质介质对小鼠动脉粥样硬化具有保护作用。n-3多不饱和脂肪酸,包括二十碳五烯酸(EPA),作为脂质介质形成的底物,可通过其同源G-蛋白偶联受体转化其潜在的抗炎和促溶作用。现研究人员对调节动脉粥样硬化疾病进展的EPA补充和脂质介质形成相关的信号通路进行研究。给Apoe-/-小鼠补充EPA后